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The field of psychiatric epidemiology has identified a
substantial list of putative risk factors for MDD. As inDepression describes both a transient mood state ex-
any nonexperimental subject, one difficulty has beenperienced by virtually all individuals at some time in
to discriminate association from causation. Four risktheir life as well as a clinical or biobehavioral syndrome,
factors stand out in the consistency of their associationusually called Major Depressive Disorder (MDD). MDD
with MDD and the level of evidence suggesting that atis a medical condition that includes abnormalities of
least some of the association is indeed causal: gender,affect and mood, neurovegetative functions (such as
stressful life events, adverse childhood experiences,appetite and sleep disturbances), cognition (such as
inappropriate guilt and feelings of worthlessness), and and certain personality traits. Across many studies, vary-
psychomotor activity (such as agitation or retardation). It ing widely in time and place, women have been shown
is one of the oldest, well-recognized medical disorders, to be at consistently greater risk for MDD than men. In
having been clearly described in medical texts dating most studies, the ratio of prevalence rates in women to
back to ancient Greece. When MDD occurs with an men has been in the range of 1.5 to 2.5. In the National
individual who has also had a history of episodes of Comorbidity Study, the lifetime prevalence of MDD in
mania, this is called Bipolar Disorder (previously termed the US population was estimated to be 21.3% in women
Manic-Depressive Illness). In this review, we will be fo- and 12.7% in men (Blazer et al., 1994). A wide range
cusing on MDD when it occurs without a history of ma- of environmental adversities such as job loss, marital
nia, where it is often called Unipolar Depressive Dis- difficulties, major health problems, and loss of close
order. personal relationships are associated with a substantial
Current diagnostic criteria for MDD (see for example increase in risk for the onset of MDD (Kessler, 1997). A
the American Psychiatric Association’s DSM-IV manual) range of difficulties in childhood including physical and
represent a clinical and historical consensus about the sexual abuse, poor parent-child relationships, and pa-
most important symptoms and signs of depressive ill- rental discord and divorce almost certainly increase the
ness. However, affected individuals display quite a wide risk for MDD later in life. Certain kinds of personality
variation in clinical symptoms and signs. Furthermore, traits appear to predispose to MDD, with the best evi-
the current diagnostic conventions are, to some degree, dence available for the trait termed “Neuroticism.” Neu-
arbitrary. Debate continues as to whether MDD is best roticism, first proposed by the British psychologist
conceptualized as a disease or as the extreme of a Eysenck, is a stable personality trait that reflects the
continuum of increasingly disturbed affective regulation. predisposition to develop emotional upset under stress.
This review outlines our current understanding of this A range of other risk factors has been proposed for
common and frequently disabling disorder and explores MDD, although in general the evidence for the existence
the challenges we face in determining the genetic and of a causal association is weaker. These would include
neurobiological basis. low social class, urban residence, separated or divorced
marital status, low levels of social support, and being
Epidemiology
in a more recently born age group. A recent WHO report
Large-scale epidemiological studies have given us, for
(Murray and Lopez, 1996) ranked depression as the
the first time, a detailed view about the current and
fourth medical condition with the greatest disease bur-lifetime prevalence of MDD. In what is probably the best
den worldwide, measured in Disability-Adjusted Lifeof these studies in the United States (called the National
Years, which express years of life lost to prematureComorbidity Survey), the lifetime prevalence of MDD,
death and years lived with a disability of specified sever-as defined by the American Psychiatric Association’s
ity and duration. The same report predicted that depres-DSM-III-R criteria, was estimated at 17%. This same
sion would be the second condition with the greatestsurvey found that nearly 5% of the population reported
disease burden worldwide by 2020 (Murray and Lopez,meeting criteria for MDD in the last 30 days (Blazer et
1996).al., 1994). As has long been suspected, MDD is probably
the most common of psychiatric disorders and, indeed,
Course of Illnessamong the most common of major biomedical condi-
MDD is not a disorder exclusively limited to adult and
elderly populations. A substantial proportion of patients‡ To whom correspondence should be addressed (e-mail: mfava@
partners.org [M. F.], kendler@hsc.vcu.edu [K. S. K.]). experience their first episodes of MDD during childhood
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and adolescence. In such occurrences of early-onset perhaps an early age at onset (Kendler et al., 1999).
Third, how do genes and environment combine toMDD, these individuals typically continue to suffer from
influence risk for MDD? Limited evidence suggests thatepisodes of MDD during adulthood as well. For most
genetic factors partially influence overall risk of illnesspeople, MDD is a life-long episodic disorder with multi-
but also influence the sensitivity of individuals to theple recurrences (averaging one episode in every 5-year
depressogenic effects of environmental adversity (Kendlerperiod), with approximately 20%–25% of major de-
et al., 1995).pressive disorder patients experiencing a chronic, unre-
The techniques of genetic epidemiology infer the mag-mitting course (Mueller and Leon, 1996). The chronic
nitude of genetic effects from the patterns of resem-and recurrent course of MDD is a major clinical issue,
blance in relatives based on the simple but powerfuloften requiring long-term prophylactic treatment.
laws of Mendel. With increasing knowledge about the
human genome, it has become feasible to identify theGenetics
chromosomal location of individual susceptibility genesMost recent family studies have reported an approxi-
for complex traits like MDD and even potentially isolatemately 3-fold increased risk for MDD in the first-degree
the genes themselves. While these techniques (linkagerelatives (parents, siblings, offspring) of individuals with
and association analysis) have proved to be relativelyMDD versus the general population, although there is
successful for simple Mendelian disorders and for asome variation, due most likely to differences in diag-
couple of complex disorders (e.g., Alzheimer’s disease),nostic and sampling (proband) criteria (Sullivan et al.,
few unequivocal findings have emerged for the major2000). From family studies alone, however, it is not pos-
psychiatric disorders. Difficulty in replication may stemsible to determine how much of the resemblance for
for a variety of causes, some inherent to the disordersrisk to MDD in relatives results from genetic factors
under study and others resulting from the researchversus family environment. MDD has been the subject
methods employed. Complex disorders, of which MDDof only three adoption studies, but well over a dozen
is a good example, are likely to involve a relatively largetwin studies. The results of the adoption studies have
number of individual genes, none of which may them-been surprisingly equivocal, with one study each show-
selves have a major impact on risk. Furthermore, theseing no evidence, weak evidence, and strong evidence
genes may interact either with each other and/or withfor the effect of genetic factors on risk to MDD (Sullivan
environmental risk factors to produce illness. Certainet al., 2000). The results of twin studies of MDD have,
genetic risk factors may only express themselves atby contrast, been both more robust and more consis-
particular developmental phases (e.g., puberty). Of thetent. We recently reviewed the results of the five twin
many conceptual and statistical problems facing thisstudies of MDD that met rigorous methodological crite-
field of complex disease genetics, one of the most criti-ria (Sullivan et al., 2000). Of these five studies, three
cal has been that of multiple testing. With many markers,were based on community samples, one on a hospital
multiple possible phenotypes and a bewildering arraysample, and one on both. Applying model-fitting jointly
of available statistical methods, applied to small andto all five of these studies, results did not differ signifi-
often under-powered samples, it can be predicted from
cantly across studies and indicated that twin resem-
statistical principles that a high proportion of observed
blance for the liability to MDD could probably be entirely
positive results obtained at traditional levels of statisti-
explained by genetic factors, although a possible small cal significance will be false positives.
influence for shared environmental factors could not be Traditional approaches to gene detection may not
ruled out. The estimate of the heritability of liability to succeed with disorders like MDD. Larger samples and
MDD in these studies was 33%, an estimate in the range a range of new statistical techniques—some of which
of that found for many common and important biomedi- will have to address critically the problem of distinguish-
cal traits such as blood pressure and serum cholesterol. ing false versus true “positive” findings—will need to be
Of the many other questions addressed in family, twin, applied. No association or linkage findings on MDD
and adoption studies of MDD, three are of particular have, to date, been sufficiently replicated to be consid-
interest. First, what is the relationship between unipolar ered established.
MDD and bipolar affective illness? The two disorders
have some familial relationship, as rates of MDD are Toward an Understanding of the Anatomical
elevated in relatives of bipolar patients. However, they and Physiological Basis of Depression
are not the same condition. In monozygotic twins con- Whereas transient mood changes are experienced by all
cordant for affective disorder, many more twins have humans and intense depression can follow a traumatic
the same form of illness (i.e., unipolar versus bipolar) experience or the loss of a loved one, depression can
than would be expected by chance. The most popular also be a symptom of many medical conditions, includ-
theory, supported by most but not all studies, suggests ing stroke, Cushing’s disease, hypothyroidism, multiple
that the two disorders share an underlying disease liabil- sclerosis, Huntington’s disease, and Parkinson’s dis-
ity, with bipolar disorder as the more severe or deviant ease. Likewise, depression can also be precipitated by
form of illness (Tsuang and Faraone, 1990). pharmacological agents such as reserpine, which de-
Second, can we distinguish on the basis of clinical pletes dopamine at synapses. Further support for bio-
history those individuals whose depressive illness is logical bases of major depressive disorder (MDD) stems
largely “genetic” versus “environmental”? The answer from some of the key symptoms of the disorder itself,
appears to be “at least partly.” Affected individuals at which include dysregulations of circadian rhythms, cog-
high familial risk for MDD tend to have recurrent epi- nitive processing, and both appetitive and psychomotor
functioning.sodes, high levels of episode-related impairment, and
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Figure 1. Response-Specific Effects
Schematic model illustrating relationships among regions mediating treatment response. Regions with known anatomical and functional
connections that also show significant changes in regional brain glucose metabolism are shown. These were measured using positron emission
tomography in hospitalized unipolar depressed patients following 6 weeks of fluoxetine treatment. Blue regions signify areas with a net
metabolic decrease with treatment; red areas are those with a net increase. Yellow signifies an area that is hypermetabolic pretreatment and
unchanged by treatment. Primary sites of action of fluoxetine are distinguished by a black border. Solid black arrows identify known reciprocal
cortico-limbic, limbic-paralimbic, and cingulate-cingulate connections. Dotted small black arrows indicate known cortical-striatal-thalamic
pathways. The model proposes that illness remission occurs when there is inhibition of paralimbic and subcortical regions and activation of
previously hypofunctioning dorsal areas, an effect facilitated by fluoxetine action in dorsal raphe, hippocampus, and posterior cingulate.
Normal or abnormal functioning of rostral cingulate (Cg24) with its bidirectional connections to both anterior cingulate (Cg24) and subgenual
cingulate (Cg25) is postulated to facilitate interactions between dorsal cortical and more ventral paralimbic systems and strategically influence
pharmacologically mediated changes in serotonergic neurotransmission across the network. The pattern of metabolic change seen in respond-
ers is not merely the correction of pretreatment abnormalities. Response to treatment, and remission or recovery, are characterized by
normalization of cortical hypometabolism, but persistent subgenual cingulate (Cg25) and hippocampal hypometabolism and rostral cingulate
(Cg24a) hypermetabolism (Cg24a), compared to normal subjects. Abbreviations: Red, dFr9/46: dorsolateral prefrontal; par40-pIns: inferior
parietal-posterior insula; dCg24: dorsal anterior cingulate; pCg23/31: posterior cingulate. Blue, Cg25: subgenual cingulate; Hth: hypothalamus;
aIns: anterior insula; ph-mT: parahippocampus-medial temporal; st-gp: caudate-putamen-globus pallidus; thal: thalamus; Hc: hippocampus.
Yellow, rCg24a: rostral anterior cingulate; numbers are Brodmann designations. Figure and caption are closely adapted from Mayberg et al.,
2000 and Mayberg et al., 1998, with the authors’ permission.
Although the anatomical and physiological basis of tensities in regions associated with the frontal cortex
and basal ganglia, and decreased bilateral frontal vol-depression is still the subject of extensive investigation,
major depression (unipolar or bipolar) most likely in- umes as well as caudate and putamen volumes. Func-
tional neuroimaging studies with SPECT and PET havevolves the limbic structures (in circuits involving the cin-
gulate-hippocampus-mamillary bodies-anterior thala- evidenced a decrease in global metabolism, with spe-
cific decreases in the frontal regions—most consistentlymus-cingulate), reward circuits (Nucleus Accumbens,
Sublenticular Extended Amygdala, Amygdala, Ventral the dorsolateral and medial–prefrontal cortex, basal
ganglia, and cingulate cortex (Dougherty and Mayberg,Tegmentum, Cingulate, Insula, Thalamus, Parahippo-
campal Gyrus, and Prefrontal cortex), hypothalamus, 2000). Blood flow and metabolism in MDD patients, how-
ever, appears to be increased in portions of orbital fron-and anterior temporal cortex (see Figure 1 [Mayberg,
1997]). Patients with strokes that affect right frontal re- tal cortex and amygdala (Drevets, 1999). In addition to
the neuroimaging-based evidence for the role of thegions may present with moods of indifference/apathy
or euphoria, whereas patients with stroke damage in basal ganglia–thalamocortical circuitry in the patho-
physiology of MDD, more recent functional neuroimag-the corresponding left frontal regions may have anxiety
or depression. ing studies of antidepressant treatment response have
suggested that the anterior cingulate cortex may alsoAlthough mood states such as depression had been
traditionally regarded to be governed solely by the limbic play a significant role (Buchsbaum et al., 1997).
There is also significant evidence, at least in the moresystem of the brain, there is now significant evidence for
the involvement in depression of numerous nonlimbic severe forms of MDD, for an enhanced activity of the
hypothalamic-pituitary-adrenocortical (HPA) system incentral nervous system structures as well. As Soares
and Mann (1997) elucidate in their review of the litera- MDD. This enhanced activity has been associated with
a greater frequency of episodic release of cortisol,ture, the best replicated structural neuroimaging find-
ings in MDD have included focal white matter hyperin- marked reductions in bone mineral density compared
Neuron
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to matched controls, and increased adrenal gland vol- Other neurotransmitter systems have also been inves-
umes. Evidence has also emerged that corticosteroid tigated. Postmortem studies have shown a selective
receptor function is impaired in many patients with major increase in the high-affinity conformation of the brain
depression and in many healthy individuals at increased a-2A-adrenoceptors as well as decreased binding to
genetic risk for an depressive disorder (Holsboer, 1999). norepinephrine transporters in the locus coeruleus of
Furthermore, clinical and preclinical data suggest that depressed patients (Klimek et al., 1997). The latter find-
unrestrained secretion of corticoctropin-releasing hor- ing was interpreted as suggesting a compensatory
mone (CRH) in the CNS produces several signs and downregulation of this transporter protein in response
symptoms of depression through continuous activation to an insufficient availability of norepinephrine at the
of CRH(1) receptors (Zobel et al., 2000). This has led to synaptic level (Klimek et al., 1997). The enhanced growth
the development of drugs that selectively antagonize hormone release in response to pyridostigmine chal-
CRH(1) receptors and to the testing of such compounds lenge in MDD has also been interpreted as suggesting
in the treatment of MDD (Zobel et al., 2000). Xie and a dysregulation in the acetylcholine neurotransmitter
McCobb (1998) provide insights into how adrenocorti- system, providing further support to animal studies link-
cotropic hormones produced in the pituitary control the ing depression with this system (Tizabi et al., 2000),
excitable properties of epinephrine-secreting cells of while the role of dopamine neurotransmission in depres-
the adrenal gland (by regulating alternative splicing of sion has been studied less extensively. In vivo receptor
the Ca21-activated K1 channel, Slo messenger RNA); a labeling studies have shown increased dopamine D2
similar mechanism may regulate cortisol synthesis and/ binding in the right striatum of MDD patients, although
or secretion. Hypercortisolemia may also be responsible a recent study has found higher striatal dopamine trans-
for causing damage to the hippocampus, as suggested porter density in major depression.
by a recent study showing smaller left hippocampal vol- Since the beneficial effects of antidepressant drugs
umes in depression (Bremner et al., 2000). In general, or ECT are observed after several weeks, investigators
however, the amounts of corticosteroid levels in MDD have proposed that these treatments require changes
are probably not as high as the levels observed in in transcription factors and gene expression (Duman et
stressed primates that suffer hippocampal damage (Sa- al., 1997). One hypothesis is that the antidepressant
polsky et al. 1990). Stress also results in the release of drugs elevate levels of brain-derived neurotrophic factor
substance P from the amygdala, and there is preliminary through cAMP and CREB-mediated effects of transcrip-
evidence in humans of antidepressant activity of sub- tion of BDNF message (Duman, Heninger, and Nestler,
stance P antagonists. 1997). Ultimately, however, the antidepressants may al-
Monoamines have been the primary focus of the ear- ter synaptic function and circuit activity as has been
lier etiological theories of MDD. Although the mono- postulated to occur in addiction (Berke and Hyman,
amine depletion hypothesis now seems to be an over- 2000).
simplified view of the pathophysiology of MDD, one
should acknowledge the historical significance of the Treatment
hypothesis, in that it has helped to develop several new
Several treatment approaches to MDD are currently
antidepressant drugs, each possessing the capability of
available. These approaches include psychotherapy,
affecting the monoamine system in a relatively selective
antidepressant medications, electroconvulsive treat-
manner. In particular, the putative role of serotonin in
ment (ECT), and other somatic therapies. Table 1 sum-MDD has been extensively studied, partly because of
marizes the advantages and disadvantages of thesethe broad therapeutic effects in depression of drugs
treatments. Although very effective, the use of ECT issuch as the selective serotonin reuptake inhibitors.
mostly limited to patients with MDD who are either highlySome, but not all, studies have shown reduced endo-
resistant to treatment, or psychotic, and the efficacy ofcrine responses to indirect or direct serotonin agonists,
other somatic therapies has not been established yet.and a recent PET study has shown that the blunting in
In the realm of psychotherapy, two types of time-limitedone of these challenges may reflect blunted metabolic
psychotherapy have been shown consistently to be ef-changes in the orbital–frontal, adjacent ventral–medial,
fective in treating MDD, interpersonal psychotherapy andand cingulate cortex (Siever et al., 1999). Postmortem
cognitive therapy. Pharmacotherapy has shown to be anstudies have shown both an increase in the density of
effective treatment for MDD, with 21 drugs having beenserotonin 5-HT-2 receptor binding sites, and a de-
approved by the Food and Drug Administration for thecreased number of serotonin 5-HT transporter binding
treatment of depression based on double-blind, pla-sites in brain tissue of depressed patients and suicide
cebo-controlled studies. The study of the efficacy ofvictims (Owens and Nemeroff, 1994), as well as an in-
these agents already marketed for depression and ofcrease in the serotonin 5-HT-1A autoreceptors in the
newer agents under investigation has been complicatedmidbrain dorsal raphe of suicide victims with major de-
by the relatively high response rates to placebo in con-pression (Stockmeier et al., 1998). This postmortem evi-
trolled trials, the inadequate duration of treatment indence for decreased serotonergic activity in MDD is
some studies (Quitkin et al., 1986), and the frequent usefurther supported by the results of recent imaging stud-
of measures of outcome with relatively lesser sensitivityies which have evidenced widespread reductions in se-
to detect differences between active and inactive treat-rotonin 5-HT-1A autoreceptor binding with positron
ments (Faries et al., 2000). More recently, a number ofemission tomography (Sargent et al., 2000) and a reduc-
compounds with putative antidepressant activity andtion in the density of brain serotonin transporter binding
pharmacological effects distinct from those of the tradi-sites among depressed patients with single photon
emission computed tomography (Malison et al., 1998). tional antidepressants, such as substance P antagonism
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Table 1. Treatments for Major Depressive Disorder
Treatments Advantages Disadvantages
Psychotherapeutic interventions (i.e., Provides useful conceptual framework, Providers of these specific forms of
cognitive-behavioral therapy, interpersonal diminishes stigma, high patient psychotherapy, which have proven efficacy
psychotherapy, behavioral therapy) acceptance. in MDD, are somewhat limited; more
commonly practiced forms of psychotherapy
(i.e., psychodynamic, supportive) typically
show marginal efficacy and little empirical
data demonstrating improved symptoms.
Traditional pharmacological approaches:
Selective serotonin reuptake inhibitors Proven antidepressant efficacy; their Although the short-term tolerability is very
(SSRIs): primary pharmacological action is the good, long-term treatment can be
citalopram, fluoxetine, fluvoxamine, blockade of uptake of serotonin (5-HT), with associated with bothersome side-effects
paroxetine, and sertraline varying degree of specificity; first-line such as sexual dysfunction, weight gain,
treatment for the great majority of insomnia, somnolence, and apathy.
practitioners; good patient acceptance
mostly due to favorable side-effect profile.
Atypical antidepressants: Proven antidepressant efficacy; their Although sexual dysfunction and, in the
bupropion, mirtazapine, nefazodone, pharmacological actions vary greatly, case of nefazodone and bupropion, weight
and trazodone with bupropion affecting primarily gain seem less common during long-term
norepinephrine (NE) and dopamine (DA) treatment with these agents than with SSRIs,
neurotransmission, mirtazapine affecting the risk for sedation in the case of trazodone
5-HT and NE neurotransmission, and and mirtazapine, and the need for b.i.d.
nefazodone and trazodone being serotonin dosing in the case of nefazodone and
5-HT2 receptor antagonists associated with bupropion may have somewhat limited the
mild reuptake inhibition of 5-HT and NE. use of these agents as first line treatment.
Serotonin norepinephrine reuptake Proven antidepressant efficacy; primary As with the SSRIs, although the short-term
inhibitors (SNRIs): pharmacological action is the blockade of tolerability is good, long-term treatment can
Venlafaxine 5-HT uptake at lower doses, and a blockade be associated with bothersome side-effects
of both 5-HT and NE uptake at higher such as sexual dysfunction, weight gain,
doses. insomnia, and somnolence.
Selective norepinephrine reuptake Proven antidepressant efficacy; primary Not yet approved by the FDA and therefore
inhibitors (SNRIs): pharmacological action is the blockade available in the U.S.; mild anticholinergic
Reboxetine of NE uptake. side-effects and tachycardia.
Tricyclic and tetracyclic antidepressants: Proven antidepressant efficacy; they used No longer first-line treatment; limited patient
amitriptyline, amoxapine, clomipramine, to be the gold standard of pharmacological acceptance mostly due to high rates of
desipramine, doxepin, imipramine, treatment anticholinergic side effects, sedation,
nortriptyline, protriptyline orthostatic hypotension, and weight gain;
and trimipramine they also affect cardiac conduction and
are lethal in overdose.
Monoamine oxidase inhibitors: Proven antidepressant efficacy; particularly Very limited patient acceptance mostly due
isocarboxazid, phenelzine, and efficacious in the atypical form of MDD to requirement of tyramine-free diet (to
tranylcypromine (i.e., mood reactivity accompanied by minimize the risk of hypertensive crises) and
hyperphagia, hypersomnia, extreme fatigue, the possibility of severe, life-threatening
and/or hypersensitivity to rejection. drug–drug interactions; they are also lethal
in overdose.
Newer pharmacological agents:
Neutraceuticals: Promising open data and double-blind No proven efficacy yet; treatment not covered
hypericum, SAMe studies with relatively small number by insurance.
of subjects.
Substance P antagonists Promising double-blind studies. Under development.
CRF antagonists Promising open data in a small number Under development.
of subjects.
Serotonin 5-HT1A partial agonists: Promising double-blind studies. Currently in phase III of development.
Gepirone
Electroconvulsive therapy Extremely effective even in treatment- Very low patient acceptability; significant
resistant cases and in depression with effects on memory and cognitive function;
psychotic features. procedures can be aversive to patients.
Other somatic therapies:
Neurosurgical procedures: Promising data from a small number of Invasive medical procedure with the potential
(e.g., cingulotomy) subjects with refractory depression. for high-risk side effects. Best procedures
remain to be established.
Transcranial magnetic stimulation (TMS) Noninvasive procedure; promising data from Limited open data in a small number
a small number of subjects with refractory of subjects; best stimulation parameters
depression. for TMS remain to be established.
Vagus nerve stimulation (VNS) Promising treatment for refractory depression Invasive procedure requiring surgery;
based on open study data; no evidence hoarseness during device activation; battery
of cognitive impairment. needs replacement every 7–10 years.
See Fava and Rosenbaum (1995) and Jarrett and Rush (1994) for details.
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and corticosteroid releasing factor (CRF) antagonism, thereby requiring subsequent interventions. There are
still many unanswered questions about MDD: (1) Whatare currently being developed and may further expand our
current pharmacopoea. The rationale for evaluating the are the susceptibility genes and their environmental
modifiers? (2) What are the pathophysiologies of theantidepressant potential of these new agents comes from
both preclinical and clinical studies, such as in the case neural systems underlying this complex disorder? (3)
How do we understand the therapeutic mechanismsof the well-documented HPA axis hyperactivation, which
has led to the development of CRF antagonists or the underlying the currently available pharmacological and
ECT approaches? And (4) how do we improve our suc-effect of tricycic antidepressants on Substance P.
Antidepressant drugs are typically classified on the cess rate in treating this highly disabling medical condi-
tion and how can we develop more rational algorithmsbases of their effects on the neuronal synapses, such
as the blockade of the reuptake of neurotransmitters or for those who do not respond to standard treatments?
Future investigations need to keep these issues in mind.the inhibition of the monoamine oxidase enzymes (Fava
and Rosenbaum, 1995). The only exception is the tricy-
Referencesclic antidepressant (TCA) group, which is identified on
the basis of its distinctive chemical structure, and is
Berke, J.D., and Hyman, S.E. (2000). Addiction, dopamine, and the
known to have relatively higher norepinephrine reuptake molecular mechanisms of memory. Neuron 25, 515–532.
inhibiting activity, relatively lower 5-HT reuptake inhib- Blazer, D.G., Kessler, R.C., McGonagle, K.A., and Swartz, M.S.
iting effect (with the exception of clomipramine), and to (1994). The prevalence and distribution of major depression in a
block several neurotransmitter receptors. These types national community sample: the National Comorbidity Survey. Am.
J. Psychiatry 151, 979–986.of classifications of antidepressant drugs have focused
Bremner, J.D., Narayan, M., Anderson, E.R., Staib, L.H., Miller, H.L.,too narrowly on synaptic pharmacology, and have failed
and Charney, D.S. (2000). Hippocampal volume reduction in majorto address the molecular and cellular changes in neural
depression. Am. J. Psychiatry 157, 115–118.functioning that are brought on as adaptations to
Buchsbaum, M.S., Wu, J., Siegel, B.V., Hackett, E., Trenary, M.,chronic administration of antidepressant drugs (Hyman
Abel, L., and Reynolds, C. (1997). Effect of sertraline on regionaland Nestler, 1996). Such changes in postreceptor signal
metabolic rate in patients with affective disorder. Biol. Psychiatry
transduction may account for the characteristic delay 41, 15–22.
in onset of efficacy with antidepressant treatment, with Dougherty, D.D., and Mayberg, H.S. (2000). Neuroimaging studies
a lag phase typically of at least 2 weeks. Alternatively, of treatment response in major depression. In Contemporary Strate-
one could postulate that this lag phase may be related gies in Psychiatric Neuroimaging Research, D.D. Dougherty and
S.L. Rauch, eds. (Washington D.C.: American Pyschiatric Press), into a reorganization of networks of neurons.
press.Despite the availability of effective treatment, we are
Drevets, W.C. (1999). Prefrontal cortical-amygdalar metabolism instill faced with the dilemma that MDD is widely underrec-
major depression. Ann. NY Acad. Sci. 877, 614–637.ognized and undertreated in the community (1990). Ap-
Duman, R.S., Heninger, G.R., and Nestler, E.J. (1997). A molecularproximately 50% of all MDD outpatients initially exposed
and cellular theory of depression. Arch. Gen. Psychiatry 54, 597–606.to either a time-limited psychotherapy targeted for de-
Faries, D., Herrera, J., Rayamajhi, J., DeBrota, D., Demitrack, M., andpression, or to a single antidepressant medication, re-
Potter, W.Z. (2000). The responsiveness of the Hamilton Depression
spond to treatment. The remaining 50% continue to Rating Scale. J. Psychiatr. Res. 34, 3–10.
experience symptoms and remain functionally impaired
Fava, M., and Rosenbaum, J.F. (1995). Pharmacotherapy and so-
after the initial treatment level (Fava and Davidson, matic therapies. In Handbook of Depression, E.E. Beckham and
1996). This large percentage of initial nonresponders W.R. Leber, eds. (New York: Guilford Publications), pp. 280–301.
presents a significant challenge to clinicians, who must Fava, M., and Davidson, K.G. (1996). Definition and epidemiology
seek out additional therapeutic measures in at least 50% of treatment-resistant depression. In The Psychiatric Clinics of North
America: Treatment Resistant Depression, Vol. 19, 179–200.of their patients in order to achieve response (Thase
Holsboer, F. (1999). The rationale for corticotropin-releasing hor-and Rush, 1995). This next-step treatment, employed
mone receptor (CRH-R) antagonists to treat depression and anxiety.after the patient does not initially respond, has not been
J. Psychiatr. Res. 33, 181–214.studied in any systematic fashion (although there are
Hyman, S.E., and Nestler, E.J. (1996). Initiation and adaptation: acontrolled clinical trials of certain treatment strategies
paradigm for understanding psychotropic drug action. Am. J. Psy-such as lithium augmentation of antidepressants) and
chiatry 153, 151–162.
is the focus of an ongoing NIMH multicenter study (Se-
Jarrett, R.B., and Rush, R.J. (1994). Short-term psychotherapy of
quenced Treatment Alternatives to Relieve Depression) depressive disorders: current status and future directions. Psychia-
that involves the enrollment and 12 month follow-up of try. Interpers. Biol. Proc. 57, 115–132.
over 4000 patients. Kendler, K.S., Kessler, R.C., Walters, E.E., MacLean, C.J., Sham,
P.C., Neale, M.C., Heath, A.C., and Eaves, L.J. (1995). Stressful life
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